SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: For instance, while ASO and CRISPRa methods for Dravet syndrome work to increase SCN1A expression in the context of LoF-mediated haploinsufficiency, these methods would be contraindicated in a recently reported subset of patients with early infantile epileptic encephalopathy in whom GoF SCN1A mutations have been identified.44 As precision medicine remains expensive and time-consuming, this introduces significant logistical and financial hurdles before its systematic introduction into the clinic.